Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors.

Rose-Hellekant TA, Skildum AJ, Zhdankin O, Greene AL, Regal RR, Kundel KD, Kundel DW.

Cancer Prev Res (Phila). 2009 May;2(5):496-502. doi: 10.1158/1940-6207.CAPR-09-0002. Epub 2009 Apr 28.

2.

Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.

Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG.

Breast. 2005 Dec;14(6):458-65. Epub 2005 Oct 19. Review.

PMID:
16236516
3.

Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.

Baumann CK, Castiglione-Gertsch M.

Minerva Ginecol. 2009 Dec;61(6):517-39. Review.

PMID:
19942839
4.

EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.

Labrie F, Labrie C, Bélanger A, Simard J, Giguère V, Tremblay A, Tremblay G.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):213-25. Review.

PMID:
11850228
5.

Antiestrogens--tamoxifen, SERMs and beyond.

Dhingra K.

Invest New Drugs. 1999;17(3):285-311. Review.

PMID:
10665480
6.

Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.

Sengupta S, Jordan VC.

Adv Exp Med Biol. 2008;630:206-19. Review.

PMID:
18637493
7.

Estrogen receptors as therapeutic targets in breast cancer.

Ariazi EA, Ariazi JL, Cordera F, Jordan VC.

Curr Top Med Chem. 2006;6(3):181-202. Review.

PMID:
16515478
8.

Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.

Robertson JF.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):209-12. Review.

PMID:
11850227
9.

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.

Labrie F, Labrie C, Bélanger A, Simard J, Gauthier S, Luu-The V, Mérand Y, Giguere V, Candas B, Luo S, Martel C, Singh SM, Fournier M, Coquet A, Richard V, Charbonneau R, Charpenet G, Tremblay A, Tremblay G, Cusan L, Veilleux R.

J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):51-84. Review.

PMID:
10418981
10.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

11.

Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).

Lewis-Wambi JS, Jordan VC.

Breast Dis. 2005-2006;24:93-105. Review.

PMID:
16917142
12.

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa H, Arteaga CL.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Review.

PMID:
11916237
13.

Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.

Peng J, Sengupta S, Jordan VC.

Anticancer Agents Med Chem. 2009 Jun;9(5):481-99. Review.

Items per page

Supplemental Content

Write to the Help Desk